UNSPSC 51171928: Bismuth subcitrate

This classification denotes a cytoprotective agent and anti-ulcer agent with the molecular formula 2C6H5O7.Bi.3K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HS813P8QPX, chemically known as 1,2,3-propanetricarboxylic acid, 2-hydroxy-, bismuth(3+) potassium salt (2:1:3) but generally known as bismuth subcitrate, which bears US NIH Compound Identifier 6335486. European Medicines Agency schedules Bismuth subcitrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13089MIG.

UNSPSC 51171928 Bismuth subcitrate is a Commodity code that captures pharmaceutical active ingredients and finished drug products procured by state and local health systems, corrections departments, and cooperative purchasing alliances. Recent state and local solicitations under this code show demand for pharmaceutical manufacturing and supply chain participation across generic multi-source drugs, direct-to-manufacturer prescription programs, and drug-testing services that may incorporate pharmaceutical screening reagents or consumables. State and local buyers issuing under this code include county corrections departments, state health and human services commissions, and multi-state cooperative purchasing alliances serving state agencies and local government facilities. The scope of work ranges from bulk generic pharmaceutical supply agreements with defined NDC codes and pricing models to specialized pharmaceutical services such as drug screening and confirmation testing for offender supervision programs.

Recent activity spans Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services, with proposals due July 23, 2026 and an estimated contract value of $600,000 over two years with three optional one-year renewals; the scope includes immunoassay screening and LC/MS/MS or GC/MS confirmation with annual demand of approximately 25,031 tests. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP posted January 20, 2026 with a March 26, 2026 proposal deadline to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to state and local facilities across Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers and achieve market availability by May 15, 2026 with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional PBM and GPO channels.